시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 글루카곤 유사 펩티드 1 시장 보고서(2025년)
Glucagon-like Peptide 1 Global Market Report 2025
상품코드 : 1775980
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,324,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,141,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,958,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

글루카곤 유사 펩티드 1의 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.4%로 305억 달러로 성장할 것입니다. 예측 기간의 성장은 경구용 glp-1 치료제의 등장, 맞춤형 의료에 대한 관심, 당뇨병 치료 알고리즘에 대한 통합, 헬스케어의 환자 중심적 접근 방식에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 신흥국 시장 확대, 새로운 제제의 규제 승인, 맞춤형 의료에 대한 관심, 환자 교육 및 인식 제고 프로그램, 경쟁 환경 등을 꼽을 수 있습니다.

향후 5년간 8.4%의 성장률 전망은 지난번 전망치보다 0.3% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 덴마크와 스위스 펩티드 원료의약품에 대한 관세가 의약품 제조비용을 증가시키기 때문에 당뇨병 치료비 상승으로 미국에 직접적으로 영향을 미칠 가능성이 높습니다. 또한, 상호 관세와 무역 마찰 및 무역 제한의 강화로 인한 세계 경제와 무역에 대한 악영향으로 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

세계 글루카곤 유사 펩티드 1 시장은 당뇨병 유병률 증가로 인해 성장할 것으로 예상됩니다. 혈당 상승을 특징으로 하는 당뇨병, 특히 제2형 당뇨병은 글루카곤-펩티드-1 제제가 체중 감소 및 혈당 조절 개선과 같은 잠재적 이점을 제공하는 질환입니다. 미국 국립의학도서관에 따르면, 2022년 1월 기준 20-79세 세계 당뇨병 유병률은 10.5%(5억 3,660만 명)로 추정되며, 2045년에는 12.2%(7억 8,320만 명)로 증가할 것으로 예측됩니다. 그 결과, 당뇨병 유병률의 증가는 글루카곤-펩티드-1 시장의 원동력이 될 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Glucagon-like peptide 1 (GLP-1) is a peptide hormone derived from amino acids and produced in the L-cells of the intestinal epithelial endocrine. This hormone is employed in the treatment of diseases such as diabetes and obesity.

The primary product types of glucagon-such as peptide 1 include Trulicity, Ozempic, Victoza, Rybelsus, and others. Trulicity, a prescription medicine administered through injection, is designed to enhance blood sugar levels. Various routes of administration, including oral, parenteral, and others, are utilized in settings such as hospitals, specialty clinics, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The escalating U.S. tariffs and rising trade tensions in spring 2025 are expected to significantly affect the chemicals sector, which is facing a disproportionate impact-particularly from tariffs on petrochemicals and intermediates, where affordable domestic alternatives are limited. Specialty chemical producers, who rely heavily on Chinese raw materials, are encountering production disruptions. Meanwhile, fertilizer manufacturers are seeing their profit margins squeezed due to tariffs on phosphate imports. In response, companies are increasing investments in R&D for bio-based alternatives, forming procurement alliances to strengthen purchasing power, and relocating production to tariff-neutral countries like Saudi Arabia.

The glucagon-such as peptide 1 market research report is one of a series of new reports from The Business Research Company that provides glucagon-such as peptide 1 market statistics, including glucagon-such as peptide 1 industry global market size, regional shares, competitors with a glucagon-such as peptide 1 market share, detailed glucagon-such as peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-such as peptide 1 industry. This glucagon-such as peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.06 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research.

The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $30.5 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.

The forecast of 8.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US by raising diabetes treatment costs, as tariffs on peptide APIs from Denmark and Switzerland increase pharmaceutical production expenses.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The global glucagon-such as peptide 1 market is anticipated to experience growth due to the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, is a condition that glucagon-such as peptide 1 medications address, particularly in the context of type 2 diabetes, offering potential benefits such as weight loss and improved blood sugar control. As of January 2022, global diabetes prevalence in individuals aged 20-79 was estimated at 10.5% (536.6 million people), with a projected increase to 12.2% (783.2 million) by 2045, according to the National Library of Medicine. Consequently, the escalating prevalence of diabetes is expected to be a driving force for the glucagon-such as peptide 1 market.

The growth of the glucagon-such as peptide 1 (GLP-1) market is further expected to be fueled by an increasing emphasis on personalized medicine. Personalized medicine involves tailoring prevention, detection, or treatment approaches based on an individual's genetic or protein-related information. This approach enables the customization of GLP-1 formulations and dosages according to the specific needs and preferences of each patient. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. Thus, the growing emphasis on personalized medicine serves as a catalyst for the glucagon-such as peptide 1 (GLP-1) market's expansion.

Technological innovations are emerging as a prominent trend in the global glucagon-such as peptide 1 market. Major companies within the market are introducing novel technologies to maintain their competitive positions. For example, Novo Nordisk A/S, a pharmaceutical company based in Denmark, has launched Wegovy, a groundbreaking once-weekly glucagon-such as peptide 1 therapy designed for weight management. Successfully completing the STEP Phase 3a clinical trial program, Wegovy demonstrated a safe and well-tolerated profile, making it an effective option for individuals struggling with obesity to achieve and sustain weight loss.

Leading companies in the glucagon-such as peptide 1 market are strategically focusing on product innovations, such as the development of oral semaglutide, to ensure their continued market presence. Oral semaglutide is a diabetes management medication delivered in pill form and taken orally. Novo Nordisk India, a healthcare company based in India, introduced oral semaglutide in January 2022. This peptide-in-a-pill formulation represents a groundbreaking advancement in diabetes treatment, providing patients with an oral alternative to injections. The innovation addresses challenges related to peptide degradation in the stomach, enhancing both stability and absorption.

In March 2024, Novo Holdings A/S, an investment company based in Denmark, acquired Catalent Inc. for $16.5 billion. This acquisition is intended to enhance Novo Holdings' presence in the rapidly growing GLP-1 market by utilizing Catalent's established infrastructure in fill-finish manufacturing. This move aims to increase capacity to meet the rising demand for treatments related to diabetes and weight loss. Catalent Inc. is a biotechnology company located in the United States that specializes in advanced delivery technologies and development solutions for pharmaceuticals.

Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

North America was the largest region in the glucagon-such as peptide 1 market in 2024. The regions covered in the glucagon-such as peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glucagon-such as peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The glucagon-such as peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glucagon-like Peptide 1 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glucagon-like peptide 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for glucagon-like peptide 1 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glucagon-like peptide 1 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Glucagon-like Peptide 1 Market Characteristics

3. Glucagon-like Peptide 1 Market Trends And Strategies

4. Glucagon-like Peptide 1 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Glucagon-like Peptide 1 Growth Analysis And Strategic Analysis Framework

6. Glucagon-like Peptide 1 Market Segmentation

7. Glucagon-like Peptide 1 Market Regional And Country Analysis

8. Asia-Pacific Glucagon-like Peptide 1 Market

9. China Glucagon-like Peptide 1 Market

10. India Glucagon-like Peptide 1 Market

11. Japan Glucagon-like Peptide 1 Market

12. Australia Glucagon-like Peptide 1 Market

13. Indonesia Glucagon-like Peptide 1 Market

14. South Korea Glucagon-like Peptide 1 Market

15. Western Europe Glucagon-like Peptide 1 Market

16. UK Glucagon-like Peptide 1 Market

17. Germany Glucagon-like Peptide 1 Market

18. France Glucagon-like Peptide 1 Market

19. Italy Glucagon-like Peptide 1 Market

20. Spain Glucagon-like Peptide 1 Market

21. Eastern Europe Glucagon-like Peptide 1 Market

22. Russia Glucagon-like Peptide 1 Market

23. North America Glucagon-like Peptide 1 Market

24. USA Glucagon-like Peptide 1 Market

25. Canada Glucagon-like Peptide 1 Market

26. South America Glucagon-like Peptide 1 Market

27. Brazil Glucagon-like Peptide 1 Market

28. Middle East Glucagon-like Peptide 1 Market

29. Africa Glucagon-like Peptide 1 Market

30. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles

31. Glucagon-like Peptide 1 Market Other Major And Innovative Companies

32. Global Glucagon-like Peptide 1 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market

34. Recent Developments In The Glucagon-like Peptide 1 Market

35. Glucagon-like Peptide 1 Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기